Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 3, Issue 9
1 September 2004
Issue Cover
All Issues
ISSN 1535-7163
EISSN 1538-8514
Issue Sections

ARTICLE

ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer
Marya F. McCarty; Jane Wey; Oliver Stoeltzing; Wenbiao Liu; Fan Fan; Corazon Bucana; Paul F. Mansfield; Anderson J. Ryan; Lee M. Ellis
View articletitled, ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer
Open the PDF for in another window
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease
Sukhdev S. Brar; Claude Grigg; Kimberly S. Wilson; Walter D. Holder, Jr.; Didier Dreau; Catherine Austin; Mareva Foster; Andrew J. Ghio; A. Richard Whorton; Grayson W. Stowell; Linda B. Whittall; Robert R. Whittle; David P. White; Thomas P. Kennedy
View articletitled, Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner <em>in vitro</em>, in mice and in a patient with metastatic disease
Open the PDF for in another window
Biological evaluation of cryptophycin 52 fragment A analogues: Effect of the multidrug resistance ATP binding cassette transporters on antitumor activity
Rima S. Al-awar; Thomas H. Corbett; James E. Ray; Lisa Polin; Joseph H. Kennedy; Margaret M. Wagner; Daniel C. Williams
View articletitled, Biological evaluation of cryptophycin 52 fragment A analogues: Effect of the multidrug resistance ATP binding cassette transporters on antitumor activity
Open the PDF for in another window
Structure-based design of a selective heparanase inhibitor as an antimetastatic agent
Keisuke Ishida; Go Hirai; Koji Murakami; Takayuki Teruya; Siro Simizu; Mikiko Sodeoka; Hiroyuki Osada
View articletitled, Structure-based design of a selective heparanase inhibitor as an antimetastatic agent
Open the PDF for in another window
In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities
Salvatore DeBonis; Dimitrios A. Skoufias; Luc Lebeau; Roman Lopez; Gautier Robin; Robert L. Margolis; Richard H. Wade; Frank Kozielski
View articletitled, <em>In vitro</em> screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities
Open the PDF for in another window
Gene expression changes induced by green tea polyphenol (−)-epigallocatechin-3-gallate in human bronchial epithelial 21BES cells analyzed by DNA microarray
Ragini Vittal; Zachariah E. Selvanayagam; Yi Sun; Jungil Hong; Fang Liu; Khew-Voon Chin; Chung S. Yang
View articletitled, Gene expression changes induced by green tea polyphenol (−)-epigallocatechin-3-gallate in human bronchial epithelial 21BES cells analyzed by DNA microarray
Open the PDF for in another window
Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2
Christine Syng-ai; A. Leela Kumari; Ashok Khar
View articletitled, Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2
Open the PDF for in another window
Differential sensitivity of cancer cells to docosahexaenoic acid–induced cytotoxicity: The potential importance of down-regulation of superoxide dismutase 1 expression
Wei-Qun Ding; Joshua L. Vaught; Hanako Yamauchi; Stuart E. Lind
View articletitled, Differential sensitivity of cancer cells to docosahexaenoic acid–induced cytotoxicity: The potential importance of down-regulation of superoxide dismutase 1 expression
Open the PDF for in another window
Gefitinib reverses breast cancer resistance protein–mediated drug resistance
Kae Yanase; Satomi Tsukahara; Sakiyo Asada; Etsuko Ishikawa; Yasuo Imai; Yoshikazu Sugimoto
View articletitled, Gefitinib reverses breast cancer resistance protein–mediated drug resistance
Open the PDF for in another window
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations
Manny D. Bacolod; Stewart P. Johnson; Anthony E. Pegg; M. Eileen Dolan; Robert C. Moschel; Nancy S. Bullock; Qingming Fang; O. Michael Colvin; Paul Modrich; Darell D. Bigner; Henry S. Friedman
View articletitled, Brain tumor cell lines resistant to <em>O</em><sup>6</sup>-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have <em>O</em><sup>6</sup>-alkylguanine-DNA alkyltransferase mutations
Open the PDF for in another window
Neuronal-associated microtubule proteins class III β-tubulin and MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs
Sima Don; Nicole M. Verrills; Tracy Y.E. Liaw; Marjorie L.M. Liu; Murray D. Norris; Michelle Haber; Maria Kavallaris
View articletitled, Neuronal-associated microtubule proteins class III β-tubulin and MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs
Open the PDF for in another window
CHK1 and CHK2 are differentially involved in mismatch repair–mediated 6-thioguanine-induced cell cycle checkpoint responses
Tao Yan; Anand B. Desai; James W. Jacobberger; R. Michael Sramkoski; Tamalette Loh; Timothy J. Kinsella
View articletitled, CHK1 and CHK2 are differentially involved in mismatch repair–mediated 6-thioguanine-induced cell cycle checkpoint responses
Open the PDF for in another window
Down-regulation of SNAIL suppresses MIN mouse tumorigenesis: Modulation of apoptosis, proliferation, and fractal dimension
Hemant K. Roy; Patrick Iversen; John Hart; Yang Liu; Jennifer L. Koetsier; Young Kim; Dhanajay P. Kunte; Madhavi Madugula; Vadim Backman; Ramesh K. Wali
View articletitled, Down-regulation of SNAIL suppresses MIN mouse tumorigenesis: Modulation of apoptosis, proliferation, and fractal dimension
Open the PDF for in another window
Chemoinducible gene therapy: A strategy to enhance doxorubicin antitumor activity
Carlos A. Lopez; Eric T. Kimchi; Helena J. Mauceri; James O. Park; Neil Mehta; Kevin T. Murphy; Michael A. Beckett; Samuel Hellman; Mitchell C. Posner; Donald W. Kufe; Ralph R. Weichselbaum
View articletitled, Chemoinducible gene therapy: A strategy to enhance doxorubicin antitumor activity
Open the PDF for in another window
Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation
Yo-ichi Yamashita; Mitsuo Shimada; Ryosuke Minagawa; Eiji Tsujita; Norifumi Harimoto; Shinji Tanaka; Ken Shirabe; Jun-ichi Miyazaki; Yoshihiko Maehara
View articletitled, Muscle-targeted <em>interleukin-12</em> gene therapy of orthotopic hepatocellular carcinoma in mice using <em>in vivo</em> electrosonoporation
Open the PDF for in another window

Advertisement

Breaking
E-cigarette Use Drops Dramatically among Kids
The NCI Calls for $11.446 Billion in Funding for FY 2026
Changes at the Top for Dana-Farber
View more recent articles
Latest News
Reprogramming Turns Cancer Cells into Immune Allies
With Vorasidenib, Glioma Treatment Continues Evolving
Cancer Research on The Ballot: Moonshot and the Future of Oncology Priorities
View more recent articles
Research Watch
X Chromosome Translocations Drive Sex Bias in a Rare Kidney Cancer Subtype
PIK3CA Mutations and Metabolic Conditions Drive Clonal Expansion in Normal Esophagus
Macrophages Scavenge Myelin to Support Glioblastoma Metabolism
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1538-8514
  • Print ISSN 1535-7163

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept